Evidence map›Paper›PMID 38250735›Full record

ArticleFrontiers in molecular biosciences2023

Design of protein-binding peptides with controlled binding affinity: the case of SARS-CoV-2 receptor binding domain and angiotensin-converting enzyme 2 derived peptides.

Giacomo Parisi, Roberta Piacentini, Alessio Incocciati, Alessandra Bonamore, Alberto Macone, Jakob Rupert, Elsa Zacco, Mattia Miotto, Edoardo Milanetti, Gian Gaetano Tartaglia and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Giacomo Parisi *Department of Basic and Applied Sciences for Engineering (SBAI), Università"Sapienza", Roma, Italy.
Roberta Piacentini *Department of Biochemical Sciences "Alessandro Rossi Fanelli", Università"Sapienza", Roma, Italy.
Alessio IncocciatiDepartment of Biochemical Sciences "Alessandro Rossi Fanelli", Università"Sapienza", Roma, Italy.
Alessandra BonamoreDepartment of Biochemical Sciences "Alessandro Rossi Fanelli", Università"Sapienza", Roma, Italy.
Alberto MaconeDepartment of Biochemical Sciences "Alessandro Rossi Fanelli", Università"Sapienza", Roma, Italy.
Jakob RupertDepartment of Biology and Biotechnologies "Charles Darwin", Università"Sapienza", Roma, Italy.
Elsa ZaccoCentre for Human Technologies (CHT), Istituto Italiano di Tecnologia (IIT), Genova, Italy.
Mattia MiottoCenter for Life Nano and Neuro Science, Istituto Italiano di Tecnologia (IIT), Roma, Italy.
Edoardo MilanettiDepartment of Physics, Università"Sapienza", Roma, Italy.
Gian Gaetano TartagliaDepartment of Biology and Biotechnologies "Charles Darwin", Università"Sapienza", Roma, Italy.
Giancarlo RuoccoCenter for Life Nano and Neuro Science, Istituto Italiano di Tecnologia (IIT), Roma, Italy.
Alberto BoffiDepartment of Biochemical Sciences "Alessandro Rossi Fanelli", Università"Sapienza", Roma, Italy.
Lorenzo Di RienzoCenter for Life Nano and Neuro Science, Istituto Italiano di Tecnologia (IIT), Roma, Italy.
Italian Institute of Technology · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of methods able to modulate the binding affinity between proteins and peptides is of paramount biotechnological interest in view of a vast range of applications that imply designed polypeptides capable to impair or favour Protein-Protein Interactions. Here, we applied a peptide design algorithm based on shape complementarity optimization and electrostatic compatibility and provided the first experimental

Indexed as

biolayer interferometry (BLI)ferritin-based nanoparticlemolecular dynamics simulationpeptide designshape complementarity

Identifiers

PMID38250735
PMCPMC10797010
OpenAlexW4390610060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.